Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 32, 35, 37 and 38; cancel claim 33; and add new claims 39-43 as follows:

Claims 1-31. (canceled)

32. (currently amended): A stability-enhanced pharmaceutical formulation of a benzamide derivative represented by the formula (1):



(1)

wherein A represents a structure shown by any one of the formula (2):



(2)

or a pharmaceutically acceptable salt thereof, comprising:

(i) said benzamide derivative or a pharmaceutically acceptable salt thereof; ~~and~~

(ii) at least one ~~stability-enhancing~~ compound selected from the group consisting of D-mannitol, sodium carboxymethyl starch, hydroxypropyl cellulose, magnesium stearate, partly pregelatinized starch, **talc and** hydroxypropylmethyl cellulose~~, dimethylacetamide,~~ **; and**

(iii) at least one compound that stabilizes said benzamide derivative or a pharmaceutically acceptable salt thereof selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, ~~ammonia,~~ monosodium fumarate, sodium dehydroacetate, sodium erythorbate, trisodium citrate and an amino compound.

33. (canceled)

34. (previously presented): The pharmaceutical formulation according to claim 32 wherein said amino compound is at least one selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatine, sodium glutamate, glycine, L-arginine, L-glutamate and carbachol.

35. (currently amended): The pharmaceutical formulation according to claim 32 further comprising at least one **compound** selected from sodium alginate and a solvent.

36. (previously presented): The pharmaceutical formulation according to claim 35 wherein said solvent is at least one selected from polyethylene glycol and propylene glycol.

37. (currently amended): The pharmaceutical formulation according to claim 32 **or claim 34** wherein the formulation is a solid formulation which comprises granules prepared by a dry granulation method.

38. (currently amended): The pharmaceutical formulation according to claim 32 **or claim 34** wherein the formulation is a liquid formulation and pH is adjusted within the range of 4 to 12.

39. (new): A stability-enhanced solid pharmaceutical formulation of a benzamide derivative represented by the formula (3):



(3)

or a pharmaceutically acceptable salt thereof, comprising:

(i) said benzamide derivative or a pharmaceutically acceptable salt thereof;

(ii) at least one compound selected from the group consisting of D-mannitol, sodium carboxymethyl starch, hydroxypropyl cellulose, magnesium stearate, partly pregelatinized starch, talc and hydroxypropylmethyl cellulose; and

(iii) at least one compound that stabilizes said benzamide derivative or a pharmaceutically acceptable salt thereof selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, monosodium fumarate, sodium dehydroacetate, sodium erythorbate, trisodium citrate and an amino compound.

40. (new): The pharmaceutical formulation according to claim 39 wherein said amino compound is at least one selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatine, sodium glutamate, glycine, L-arginine, L-glutamate and carbachol.

41. (new): The pharmaceutical formulation according to claim 39 further comprising at least one compound selected from sodium alginate and a solvent.

42. (new): The pharmaceutical formulation according to claim 41 wherein said solvent is at least one selected from polyethylene glycol and propylene glycol.

43. (new): The pharmaceutical formulation according to claim 39 or claim 40 wherein the formulation comprises granules prepared by a dry granulation method.